Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent Exherin (ADH 1) administered once daily for 5 consecutive days by intravenous infusion in subjects with N-cadherin expressing, incurable, solid tumours (Adherex protocol number AHX 01 003)
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2006
At a glance
- Drugs ADH 1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 30 Oct 2005 New trial record.